A portion of the funding, which is from the government of the Wallonia region of Belgium, is repayable over 12 years.
VolitonRx's research-use-only kits can be used to examine patterns in circulating nucleosomes in disease models, preclinical testing, and clinical trials.
The test combines two previously CE marked assays that are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features.
The company also plans to get started this year on preparations for bringing future tests through the US Food and Drug Administration.
The company is working with DKFZ to evaluate its NuQ test, which can identify chromosome fragments circulating in blood and analyze them for epigenetic modifications.
The tests are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features such as histone modifications.
The blood-based assay, which uses the company's nucleosome detection technology, is the first of several that will be bundled together as a test for cancer diagnosis.
The study will evaluate the ability of VolitionRx's technology to detect prostate cancer and to distinguish different prostate conditions and healthy samples.
The IP covers the detection of histone modifications in cell-free nucleosomes from circulating cancer cells.
The firm closed its offering of 2,475,000 shares of stock at a price of $3.75 per share. It plans to use the proceeds to fund colorectal cancer clinical trials.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.